Abstract
Background: A monoclonal antibody (mAb) 2F5 binds to the membrane‐proximal external region (MPER) of the transmembrane subunit gp41 of human immunodeficiency virus type 1 (HIV‐1) is known to broadly neutralize HIV‐1 strains. The Adenovirus type 5 vector (Ad5) has been widely applied for HIV‐1 vaccine, and hexon hypervariable region 5 (HVR5) is exposed on viral surface and easily target host immune responses against Ad5.Methods: We constructed a recombinant adenovirus type 5 vector (rAd5) with a 2F5‐binding epitope (ELDKWA) of MPER on Ad5‐HVR5. In addition, we developed rAd5 encoding the HIV‐1IIIB envelope (Env) gene for the induction of Env‐specific cellular immunity.Results: The virus titers of the constructed rAd5 were similar to that of the parental Ad5 vector. Furthermore, high‐dose immunization of rAd5 induced Env‐specific CD8+ cells and high levels of anti‐ELDKWA antibodies. Moreover, an in vitro HIV‐1 neutralization assay indicated that ELDKWA‐specific mAbs derived from rAd5‐immunized mice neutralized a wide range of HIV‐1 strains.Conclusions: The present study outlines the development of an Ad5‐based HIV‐1 vaccine targeting the hypervariable regions of Ad5. The constructed rAd5 induced an HIV‐1‐specific cellular immune response and neutralizing antibodies against various strains of HIV‐1 simultaneously. Copyright © 2008 John Wiley & Sons, Ltd.

This publication has 64 references indexed in Scilit: